Zimmer Biomet Holdings Inc (Zimmer Biomet) designs, manufactures, and commercializes reconstructive products; dental implants; sports medicine, biologics, extremities, and trauma products; spine, craniomaxillofacial and thoracic products; and related surgical products. It serves neurosurgeons, orthopedic surgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare purchasing organizations, healthcare dealers, and other specialists.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Zimmer Biomet focuses on the development of new surgical techniques, including robotic techniques, biologics, materials, and product designs. The company also focuses on developing new technologies and expanding its product categories through strategic alliances and acquisitions. In FY2022, Zimmer Biomet spent US$406 million on its R&D activities, which as a percentage of revenue, amounted to 5.9%. It has more than 2,100 employees working on its R&D activities. Its primary R&D facility is in Warsaw, Indiana; and other facilities are in China, Canada, France, Switzerland, and the US. At the end of 2022, Zimmer Biomet had over 6,000 issued patents and patent applications throughout the world.